AML-221: Liposomal Annamycin Overcomes MDR and Has No Cardiac Toxicity in Two Clinical Trials for the Second-Line Treatment of R/R AML

Robert Shepard

DOI: https://doi.org/10.1016/s2152-2650(20)30736-9

2020-09-01

Abstract:Context This study is determining the lack of any cardiotoxicity and efficacy of L-Annamycin for the second-line treatment of R/R AML. Objective To demonstrate the safety and efficacy of L-Annamycin leading to its approval as the only approved therapy for most patients with R/R AML agnostic of mutational status. Design Two new phase Ib/IIa clinical trials were started in both the U.S. and Europe in 2018 using L-Annamycin for the second-line treatment of R/R AML. These are ongoing proof-of-concept studies that will hopefully lead to accelerated approval for this indication. All patients have received 3 days of intravenous L-Annamycin over 2 hours. Patients are being evaluated for efficacy using the International Working Group response criteria. For the efficacy analysis, 21 subjects will be evaluated and compared to historical controls. All patients will be followed, and OS, as well as subsequent therapies if any (including SCT) will be captured. An update to these results will be presented. Setting All patients are being treated in tertiary care academic medical centers specializing in hematological malignancies and hematopoietic SCT in both Poland and the U.S. Patients Patients who have primarily refractory AML or who have relapsed with AML are eligible for the study. The EF must be >50% to receive therapy. The study is a 3+3 dose escalation followed by an expansion cohort to evaluate safety, toxicity, and efficacy. Two cohorts have been completed in the U.S., and the study met its primary endpoint of safety. There were no SAEs or DLTs, and no patients were withdrawn because of adverse events. In Poland, the first four cohorts have finished, again without any SAEs or DLTs, and no patients were withdrawn because of adverse events. Intervention L-Annamycin IV over 2 hours qd × 3d Main outcome measures 1. Safety; 2. PR and CR according to International Working Group criteria for AML; 3. Assessment of any cardiotoxicity as determined by 3D echocardiography with strain analysis and cardiotoxicity biomarkers, including troponins levels. Results To date, the U.S. study has met its primary endpoint of safety. There were no SAEs or DLTs. No patient was withdrawn due to toxicity. There was one CRi and one PR in the six patients treated. The Polish study has enrolled the first four cohorts and the first patient in the fifth cohort. Of the 13 patients, 7 had relapsed AML, and 6 had primarily refractory AML. As in the U.S., there have been no SAEs, DLTs, or patients withdrawn. There have been no decreases in EF, and all cardiotoxicity markers have remained normal. Dose escalation continues to reach a therapeutic dose. Conclusions Absolutely no cardiotoxicity has been seen, along with preliminary evidence of efficacy. The investigational agent has received fast track and orphan designation in the U.S. A meeting with the FDA has been scheduled to ask for a single-arm phase 2 study for accelerated approval. If successful, this will be the first approved therapy for all patients with R/R AML agnostic of mutational status. Funding The study is supported by funding from the sponsor, Moleculin Biotech, LLC.

oncology,hematology